Format

Send to

Choose Destination
Infect Dis Clin North Am. 2019 Jun;33(2):523-544. doi: 10.1016/j.idc.2019.02.004. Epub 2019 Mar 30.

Respiratory Virus Infections of the Stem Cell Transplant Recipient and the Hematologic Malignancy Patient.

Author information

1
Division of Infectious Disease, Department of Medicine, Oregon Health and Science University, 3181 Southwest Sam Jackson Park Road, Mail Code L457, Portland, OR 97239, USA. Electronic address: fontanla@ohsu.edu.
2
Division of Infectious Disease, Department of Medicine, Oregon Health and Science University, 3181 Southwest Sam Jackson Park Road, Mail Code L457, Portland, OR 97239, USA.

Abstract

Respiratory virus infections in hematologic stem cell transplant recipients and patients with hematologic malignancies are increasingly recognized as a cause of significant morbidity and mortality. The often overlapping clinical presentation makes molecular diagnostic strategies imperative for rapid diagnosis and to inform understanding of the changing epidemiology of each of the respiratory viruses. Most respiratory virus infections are managed with supportive therapy, although there is effective antiviral therapy for influenza. The primary focus should remain on primary prevention infection control procedures and isolation precautions, avoidance of ill contacts, and vaccination for influenza.

KEYWORDS:

Coronavirus; Hematopoietic stem cell transplant; Human metapneumovirus; Influenza; Parainfluenza; RSV; Respiratory virus infection; Rhinovirus

PMID:
30940462
DOI:
10.1016/j.idc.2019.02.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center